Logo image of INFI

INFINITY PHARMACEUTICALS INC (INFI) Stock Price, Quote, News and Overview

NASDAQ:INFI - Nasdaq - US45665G3039 - Common Stock - Currency: USD

0.0447  -0.04 (-46.98%)

After market: 0.04 0 (-10.51%)

INFI Quote, Performance and Key Statistics

INFINITY PHARMACEUTICALS INC

NASDAQ:INFI (9/13/2023, 8:17:37 PM)

After market: 0.04 0 (-10.51%)

0.0447

-0.04 (-46.98%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.33
52 Week Low0.03
Market Cap4.06M
Shares90.76M
Float88.28M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-13 2023-11-13/amc
IPO07-27 2000-07-27


INFI short term performance overview.The bars show the price performance of INFI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

INFI long term performance overview.The bars show the price performance of INFI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of INFI is 0.0447 USD. In the past month the price decreased by -49.26%. In the past year, price decreased by -96.66%.

INFINITY PHARMACEUTICALS INC / INFI Daily stock chart

INFI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About INFI

Company Profile

INFI logo image Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Company Info

INFINITY PHARMACEUTICALS INC

1100 Massachusetts Avenue, Floor 4

Cambridge MASSACHUSETTS 02138 US

CEO: Adelene Q. Perkins

Employees: 30

Company Website: https://www.infi.com/

Phone: 16174531000.0

INFINITY PHARMACEUTICALS INC / INFI FAQ

What is the stock price of INFINITY PHARMACEUTICALS INC today?

The current stock price of INFI is 0.0447 USD. The price decreased by -46.98% in the last trading session.


What is the ticker symbol for INFINITY PHARMACEUTICALS INC stock?

The exchange symbol of INFINITY PHARMACEUTICALS INC is INFI and it is listed on the Nasdaq exchange.


On which exchange is INFI stock listed?

INFI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INFINITY PHARMACEUTICALS INC stock?

6 analysts have analysed INFI and the average price target is 0.31 USD. This implies a price increase of 584.56% is expected in the next year compared to the current price of 0.0447. Check the INFINITY PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INFINITY PHARMACEUTICALS INC worth?

INFINITY PHARMACEUTICALS INC (INFI) has a market capitalization of 4.06M USD. This makes INFI a Nano Cap stock.


How many employees does INFINITY PHARMACEUTICALS INC have?

INFINITY PHARMACEUTICALS INC (INFI) currently has 30 employees.


Is INFINITY PHARMACEUTICALS INC (INFI) expected to grow?

The Revenue of INFINITY PHARMACEUTICALS INC (INFI) is expected to grow by 1.89% in the next year. Check the estimates tab for more information on the INFI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INFINITY PHARMACEUTICALS INC (INFI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INFINITY PHARMACEUTICALS INC (INFI) stock pay dividends?

INFI does not pay a dividend.


When does INFINITY PHARMACEUTICALS INC (INFI) report earnings?

INFINITY PHARMACEUTICALS INC (INFI) will report earnings on 2023-11-13, after the market close.


What is the Price/Earnings (PE) ratio of INFINITY PHARMACEUTICALS INC (INFI)?

INFINITY PHARMACEUTICALS INC (INFI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).


INFI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INFI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to INFI. INFI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INFI Financial Highlights

Over the last trailing twelve months INFI reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 5.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%17.61%
Sales Q2Q%-15.01%
EPS 1Y (TTM)5.66%
Revenue 1Y (TTM)15.88%

INFI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to INFI. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 6.16% and a revenue growth 1.89% for INFI


Ownership
Inst Owners0%
Ins Owners3.33%
Short Float %N/A
Short RatioN/A
Analysts
Analysts43.33
Price Target0.31 (593.51%)
EPS Next Y6.16%
Revenue Next Year1.89%